Urogynaecological research: current and future developments.

摘要

The massive introduction of new products from device and drug industries together with a scanty device approval process and a growing scepticism about the reliability of drug trials call for new improved strategies in urogynaecological research. Device companies and physicians have a mutual ethical responsibility of contributing to create clinical data based on the framework of trials in surgery before new surgical products are implemented and disseminated. In respect of the patients' altruism and confidence, which make drug trials possible, the industry and academia have an obligation to conduct and report clinical results in accordance with the highest standards of scientific and ethical integrity.